Literature DB >> 23482793

The value of PET compared to MRI in malignant head and neck tumors.

Thomas Guenzel1, Achim Franzen, Susanne Wiegand, Sabine Kraetschmer, Johann Ludwig Jahn, Robert Mironczuk, Thomas Wilhelm, Thomas Schrom.   

Abstract

BACKGROUND: Reliable diagnosis plays an important role in the early detection of head and neck tumors. The objective of this study was to compare the value and clinical relevance of magnetic resonance imaging (MRI) and positron emission tomography (PET) regarding the assessment and the identification of head and neck tumors. PATIENTS AND METHODS: From January 1, 2005, to January 1, 2007, 120 patients suffering from carcinomas of the oropharynx and larynx were examined by means of MRI and PET.
RESULTS: The difference between sensitivity and specificity of MRI and PET was not significant with regard to the diagnosis of primary tumors, recurrence, or cancer of unknown primary. A statistically significant difference between both methods only occurred for detectron of malignant lymph nodes of size >10 mm.
CONCLUSION: In particular, the assessment of small tumors by MRI and PET is characterized by a high number of false-negative findings. The future of diagnostic imaging is likely to be a combination of both techniques, as a hybrid technique.

Entities:  

Mesh:

Year:  2013        PMID: 23482793

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer.

Authors:  K Kubiessa; S Purz; M Gawlitza; A Kühn; J Fuchs; K G Steinhoff; A Boehm; O Sabri; R Kluge; T Kahn; P Stumpp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-29       Impact factor: 9.236

2.  Imaging at diagnosis impacts cancer-specific survival among patients with cancer of the oropharynx.

Authors:  Rustain L Morgan; Megan M Eguchi; Adam C Mueller; Stacie L Daugherty; Arya Amini; Sana D Karam
Journal:  Cancer       Date:  2019-05-01       Impact factor: 6.860

3.  SUVmax for predicting regional control in oropharyngeal cancer.

Authors:  Lisa W Lekanne Dit Deprez; Grégoire B Morand; Christian Thüring; Shila Pazahr; Martin W Hüllner; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-15       Impact factor: 2.503

4.  Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma.

Authors:  Jingting Wang; Yandong Zhou; Jianguang Lu; Yanan Sun; Hui Xiao; Ming Liu; Linli Tian
Journal:  Med Oncol       Date:  2014-08-07       Impact factor: 3.064

Review 5.  MicroRNAs in laryngeal cancer: implications for diagnosis, prognosis and therapy.

Authors:  Pei Li; Hui Liu; Zhiyuan Wang; Feng He; Haifeng Wang; Zhi Shi; Ankui Yang; Jin Ye
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

Review 6.  Computed tomography versus magnetic resonance imaging for diagnosing cervical lymph node metastasis of head and neck cancer: a systematic review and meta-analysis.

Authors:  J Sun; B Li; C J Li; Y Li; F Su; Q H Gao; F L Wu; T Yu; L Wu; L J Li
Journal:  Onco Targets Ther       Date:  2015-06-08       Impact factor: 4.147

7.  Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study.

Authors:  Carsten Pietsch; Felipe de Galiza Barbosa; Martin W Hüllner; Daniel T Schmid; Stephan K Haerle; Gerhard F Huber; Gabriela Studer; Thomas F Hany; Patrick Veit-Haibach
Journal:  BMC Med Imaging       Date:  2015-12-29       Impact factor: 1.930

8.  Submandibular lymph node metastasis of occult thyroid carcinoma first suspected to be a salivary gland tumor: a case report.

Authors:  Hiroyuki Kaneko; Mami Deguchi; Hisashi Yano
Journal:  J Med Case Rep       Date:  2021-07-23

9.  Evaluation of Contrast-Enhanced Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) in the Detection of Retropharyngeal Lymph Node Metastases in Nasopharyngeal Carcinoma Patients.

Authors:  Jie Chen; Jingwen Luo; Xia He; Chenjing Zhu
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.